Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CogstateASX:CGS -0.36%80 Cash-to-Debt is 82.00 as of Dec. 2025, which is 76% above its 10-year median of 46.70. GuruFocus rates ASX:CGS with a GF Score™ of 80/100 and a GF Value™ of A$2.09 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Cogstate ranks better than 89.54% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cogstate's cash to debt ratio for the quarter that ended in Dec. 2025 was 82.00.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cogstatecould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Cogstate's Cash-to-Debt or its related term are showing as below:
ASX:CGS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.92 Med: 46.7 Max: No Debt
Current: 82
During the past 13 years, Cogstate's highest Cash to Debt Ratio was No Debt. The lowest was 1.92. And the median was 46.70.
ASX:CGS's Cash-to-Debt is ranked better than 89.54% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 0.78
vs ASX:CGS: 82.00
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cogstate Cash-to-Debt Related Terms
Cogstate Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cogstate's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:CGS vs VEEV, BTSG, HQY: Cash-to-Debt Comparison
For the Health Information Services subindustry, Cogstate's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cogstate's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogstate (ASX:CGS) has a Cash-to-Debt of 82.00 as of Dec. 2025. This is 76% above median its historical median of 46.70. Over the past decade, Cogstate's Cash-to-Debt has ranged from 1.92 to 10,000.00. According to the industry distribution chart, Cogstate ranks #70 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 10.5%.
Is Cogstate's Cash-to-Debt too high?
Cogstate's current Cash-to-Debt of 82.00 is 76% above median its 10-year median of 46.70. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 10,000.00. The Healthcare Providers & Services industry median Cash-to-Debt is 0.78. Cogstate's value of 82.00 is 10412.8% above this industry median. Based on the distribution chart, Cogstate ranks #70 out of 669 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cogstate has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #70 out of 669 companies for Cash-to-Debt. This places Cogstate in the top 11% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.78. Cogstate's value of 82.00 is 10412.8% above this benchmark. Historically, Cogstate's own Cash-to-Debt has ranged from 1.92 to 10,000.00 over the past decade. While the company's 10-year median is 46.70 vs. the industry median of 0.78, Cogstate has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.78, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current Cash-to-Debt of 82.00 is 10412.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current Cash-to-Debt is 82.00, which is 76% above median its own 10-year median of 46.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$2.09, compared to a current price of A$2.79 — trading 33.5% above its estimated fair value. The current Cash-to-Debt is 82.00, which is 76% above median its 10-year median of 46.70 and 10412.8% above the Healthcare Providers & Services industry median of 0.78. Cogstate's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current Cash-to-Debt is 82.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (ASX:CGS) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of A$2.79 is trading 33.5% above its estimated GF Value™ of A$2.09.
GuruFocus considers Cogstate to be Significantly Overvalued.
Key valuation signals for ASX:CGS:
Cash-to-Debt: 82.00 (76% above median its 10-year median of 46.70)
GF Value™: A$2.09 vs. price of A$2.79 (33.5% above fair value)
Industry Position: 10412.8% above the Healthcare Providers & Services median (#70 of 669)
No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
80GF Score
Get the complete analysis for ASX:CGS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CGS has been successfully added to your 
